Immune thrombocytopenic purpura: A rare side effect in a patient treated with Imiquimod for lentigo maligna
Topical Imiquimod is increasingly used in the treatment of lentigo maligna (LM) for patients not suitable or willing for surgery. It acts as an immune response modifier and is recommended for use with caution in patients with autoimmune disorders. A review of the literature did not reveal any report...
Main Authors: | E.A. Whatling, K. Balghari, B.W.E.M. Powell |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-09-01
|
Series: | JPRAS Open |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352587817300360 |
Similar Items
-
Topical Imiquimod Treatment of Lentigo Maligna
by: F. Ventura, et al.
Published: (2009-10-01) -
Clinical and histologic features associated with lentigo maligna clearance after imiquimod treatment
by: R. Kwak, et al.
Published: (2022-05-01) -
Topical Treatment of Melanoma In Situ, Lentigo Maligna, and Lentigo Maligna Melanoma with Imiquimod Cream: A Systematic Review of the Literature
by: Silvia Vaienti, et al.
Published: (2023-08-01) -
Long-Term Follow-Up of Lentigo Maligna Patients Treated with Imiquimod 5% Cream
by: S. Morteza Seyed Jafari, et al.
Published: (2023-02-01) -
Clinical and histopathological features of lentigo maligna and lentigo maligna melanoma: a retrospective analysis in Korea
by: Chanyong Park, et al.
Published: (2024-01-01)